Victory Capital Management Inc. Acquires 377,883 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Victory Capital Management Inc. raised its stake in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 32.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,526,309 shares of the company's stock after acquiring an additional 377,883 shares during the period. Victory Capital Management Inc. owned 3.30% of Omnicell worth $67,951,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the company. Smartleaf Asset Management LLC increased its stake in Omnicell by 51.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock valued at $35,000 after buying an additional 273 shares during the period. Van ECK Associates Corp boosted its stake in Omnicell by 47.0% during the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company's stock valued at $44,000 after purchasing an additional 315 shares in the last quarter. First Horizon Advisors Inc. increased its position in shares of Omnicell by 36.3% during the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock valued at $59,000 after purchasing an additional 355 shares during the period. Redmond Asset Management LLC raised its stake in shares of Omnicell by 0.3% in the 4th quarter. Redmond Asset Management LLC now owns 121,209 shares of the company's stock worth $5,396,000 after buying an additional 371 shares in the last quarter. Finally, Curi RMB Capital LLC lifted its holdings in shares of Omnicell by 0.7% in the third quarter. Curi RMB Capital LLC now owns 88,815 shares of the company's stock valued at $3,872,000 after buying an additional 651 shares during the period. Institutional investors own 97.70% of the company's stock.

Remove Ads

Insider Activity

In related news, Director Mark W. Parrish sold 12,000 shares of the business's stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total transaction of $567,600.00. Following the sale, the director now owns 58,427 shares in the company, valued at $2,763,597.10. The trade was a 17.04 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 2.64% of the company's stock.

Omnicell Stock Down 2.8 %

NASDAQ OMCL traded down $1.05 during trading hours on Monday, hitting $35.94. 476,876 shares of the company traded hands, compared to its average volume of 491,461. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. The business's 50-day moving average is $41.74 and its 200-day moving average is $43.64. The stock has a market capitalization of $1.68 billion, a price-to-earnings ratio of 133.12, a P/E/G ratio of 7.53 and a beta of 0.85. Omnicell, Inc. has a twelve month low of $25.12 and a twelve month high of $55.75.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. Sell-side analysts anticipate that Omnicell, Inc. will post 1.09 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Benchmark reaffirmed a "buy" rating and set a $62.00 target price on shares of Omnicell in a report on Tuesday, February 4th. JPMorgan Chase & Co. upped their target price on Omnicell from $37.00 to $44.00 and gave the stock a "neutral" rating in a research report on Thursday, November 21st. StockNews.com upgraded shares of Omnicell from a "hold" rating to a "buy" rating in a report on Thursday. Bank of America lowered their target price on shares of Omnicell from $54.00 to $46.00 and set a "neutral" rating on the stock in a research note on Monday, January 6th. Finally, Wells Fargo & Company cut their target price on shares of Omnicell from $49.00 to $40.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and an average price target of $52.33.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.